Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017 (2017), Article ID 5453606, 14 pages
https://doi.org/10.1155/2017/5453606
Review Article

Imaging of Myocardial Fibrosis in Patients with End-Stage Renal Disease: Current Limitations and Future Possibilities

1John Walls Renal Unit, Leicester General Hospital, Leicester, UK
2National Centre for Sport and Exercise Medicine, School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UK
3Department of Cardiovascular Science, NIHR Leicester Cardiovascular Biomedical Research Unit, Leicester, UK
4Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, UK

Correspondence should be addressed to M. P. M. Graham-Brown; ku.ca.el@1bgmpm

Received 18 October 2016; Revised 30 January 2017; Accepted 12 February 2017; Published 2 March 2017

Academic Editor: Marco Francone

Copyright © 2017 M. P. M. Graham-Brown et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. N. Foley, P. S. Parfrey, and M. J. Sarnak, “Epidemiology of cardiovascular disease in chronic renal disease,” Journal of the American Society of Nephrology, vol. 9, no. 12, pp. S16–S23, 1998. View at Google Scholar · View at Scopus
  2. U.S. Renal Data System, USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, 2013.
  3. C. Wanner, V. Krane, W. März et al., “Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis,” New England Journal of Medicine, vol. 353, no. 3, pp. 238–248, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. C. A. Herzog, J. W. Strief, A. J. Collins, and D. T. Gilbertson, “Cause-specific mortality of dialysis patients after coronary revascularization: why don't dialysis patients have better survival after coronary intervention?” Nephrology Dialysis Transplantation, vol. 23, no. 8, pp. 2629–2633, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Y. Y. Chiu, S. Sinha, P. A. Kalra, and D. Green, “Sudden cardiac death in haemodialysis patients: preventative options,” Nephrology, vol. 19, no. 12, pp. 740–749, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. M. A. Rossi, “Connective tissue skeleton in the normal left ventricle and in hypertensive left ventricular hypertrophy and chronic chagasic myocarditis,” Medical Science Monitor, vol. 7, no. 4, pp. 820–832, 2001. View at Google Scholar · View at Scopus
  7. K. H. W. J. Ten Tusscher and A. V. Panfilov, “Influence of diffuse fibrosis on wave propagation in human ventricular tissue,” Europace, vol. 9, supplement 6, pp. vi38–vi45, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Mall, W. Huther, J. Schneider, P. Lundin, and E. Ritz, “Diffuse intermyocardiocytic fibrosis in uraemic patients,” Nephrology Dialysis Transplantation, vol. 5, no. 1, pp. 39–44, 1990. View at Publisher · View at Google Scholar · View at Scopus
  9. B. Villari, S. E. Campbell, O. M. Hess et al., “Influence of collagen network on left ventricular systolic and diastolic function in aortic valve disease,” Journal of the American College of Cardiology, vol. 22, no. 5, pp. 1477–1484, 1993. View at Publisher · View at Google Scholar · View at Scopus
  10. R. O'Hanlon, A. Grasso, M. Roughton et al., “Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy,” Journal of the American College of Cardiology, vol. 56, no. 11, pp. 867–874, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. R. G. Assomull, S. K. Prasad, J. Lyne et al., “Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy,” Journal of the American College of Cardiology, vol. 48, no. 10, pp. 1977–1985, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. Z. H. Tseng, P. Ursell, B. Colburn et al., “Interstitial myocardial fibrosis is associated with arrhythmic sudden death,” Journal of the American College of Cardiology, vol. 61, no. 10, article E345, 2013. View at Publisher · View at Google Scholar
  13. J. M. ter Maaten, K. Damman, M. C. Verhaar et al., “Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation,” European Journal of Heart Failure, vol. 18, no. 6, pp. 588–598, 2016. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Díez, A. González, B. López, and R. Querejeta, “Mechanisms of disease: pathologic structural remodeling is more than adaptive hypertrophy in hypertensive heart disease,” Nature Clinical Practice Cardiovascular Medicine, vol. 2, no. 4, pp. 209–216, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Westermann, M. Kasner, P. Steendijk et al., “Role of left ventricular stiffness in heart failure with normal ejection fraction,” Circulation, vol. 117, no. 16, pp. 2051–2060, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. F. Weidemann, S. Herrmann, S. Störk et al., “Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis,” Circulation, vol. 120, no. 7, pp. 577–584, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. N. Mewton, C. Y. Liu, P. Croisille, D. Bluemke, and J. A. C. Lima, “Assessment of myocardial fibrosis with cardiovascular magnetic resonance,” Journal of the American College of Cardiology, vol. 57, no. 8, pp. 891–903, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. B. López, A. González, N. Hermida, C. Laviades, and J. Díez, “Myocardial fibrosis in chronic kidney disease: potential benefits of torasemide,” Kidney International, vol. 74, no. 111, pp. S19–S23, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Díez and C. Laviades, “Hipertensive heart disease in the patient with chronic kidney disease,” Nefrologia, vol. 28, no. 2, pp. 135–142, 2008. View at Google Scholar · View at Scopus
  20. F. Locatelli, P. Pozzoni, F. Tentori, and L. Del Vecchio, “Epidemiology of cardiovascular risk in patients with chronic kidney disease,” Nephrology Dialysis Transplantation, vol. 18, supplement 7, pp. vii2–vii9, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Levin, J. Singer, C. R. Thompson, H. Ross, and M. Lewis, “Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention,” American Journal of Kidney Diseases, vol. 27, no. 3, pp. 347–354, 1996. View at Publisher · View at Google Scholar · View at Scopus
  22. R. N. Foley, P. S. Parfrey, J. D. Harnett et al., “Clinical and echocardiographic disease in patients starting end-stage renal disease therapy,” Kidney International, vol. 47, no. 1, pp. 186–192, 1995. View at Publisher · View at Google Scholar · View at Scopus
  23. B. M. Curtis and P. S. Parfrey, “Congestive heart failure in chronic kidney disease: disease-specific mechanisms of systolic and diastolic heart failure and management,” Cardiology Clinics, vol. 23, no. 3, pp. 275–284, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. R. J. Glassock, R. Pecoits-Filho, and S. H. Barberato, “Left ventricular mass in chronic kidney disease and ESRD,” Clinical Journal of the American Society of Nephrology, vol. 4, supplement 1, pp. S79–S91, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. G. M. London, B. Pannier, A. P. Guerin et al., “Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study,” Journal of the American Society of Nephrology, vol. 12, no. 12, pp. 2759–2767, 2001. View at Google Scholar · View at Scopus
  26. W. Linz, G. Wiemer, J. Schaper et al., “Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis,” Molecular and Cellular Biochemistry, vol. 147, no. 1-2, pp. 89–97, 1995. View at Publisher · View at Google Scholar · View at Scopus
  27. F. Simko and O. Pechanova, “Remodelling of the heart and vessels in experimental hypertension: advances in protection,” Journal of Hypertension, vol. 28, supplement 1, pp. S1–S6, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. H. P. Krayenbuehl, O. M. Hess, E. S. Monrad, J. Schneider, G. Mall, and M. Turina, “Left ventricular myocardial structure in aortic valve disease before, intermediate, and late after aortic valve replacement,” Circulation, vol. 79, no. 4, pp. 744–755, 1989. View at Publisher · View at Google Scholar · View at Scopus
  29. C. T. Chan, G. H. Li, A. Valaperti, and P. Liu, “Intensive hemodialysis preserved cardiac injury,” ASAIO Journal, vol. 61, no. 5, pp. 613–619, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. A. E. Becker, C. D. Heijmans, and C. E. Essed, “Chronic non-ischaemic congestive heart disease and endomyocardial biopsies. Worth the extra?” European Heart Journal, vol. 12, no. 2, pp. 218–223, 1991. View at Publisher · View at Google Scholar · View at Scopus
  31. A. S. Flett, M. P. Hayward, M. T. Ashworth et al., “Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans,” Circulation, vol. 122, no. 2, pp. 138–144, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. A. A. Shiozaki, T. Senra, E. Arteaga et al., “Myocardial fibrosis detected by cardiac CT predicts ventricular fibrillation/ventricular tachycardia events in patients with hypertrophic cardiomyopathy,” Journal of Cardiovascular Computed Tomography, vol. 7, no. 3, pp. 173–181, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. A. A. Shiozaki, T. S. G. Santos, E. Artega, and C. E. Rochitte, “Myocardial delayed enhancement by computed tomography in hypertrophic cardiomyopathy,” Circulation, vol. 115, no. 17, pp. e430–e431, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. D. Y. Y. Chiu, D. Green, N. Abidin, S. Sinha, and P. A. Kalra, “Cardiac imaging in patients with chronic kidney disease,” Nature Reviews Nephrology, vol. 11, no. 4, pp. 207–220, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. L. N. Bohs and G. E. Trahey, “A novel method for angle independent ultrasonic imaging of blood flow and tissue motion,” IEEE Transactions on Biomedical Engineering, vol. 38, no. 3, pp. 280–286, 1991. View at Publisher · View at Google Scholar · View at Scopus
  36. B. Pirat, D. S. Khoury, C. J. Hartley et al., “A novel feature-tracking echocardiographic method for the quantitation of regional myocardial function. Validation in an animal model of ischemia-reperfusion,” Journal of the American College of Cardiology, vol. 51, no. 6, pp. 651–659, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Chen, T. Cao, Y. Duan, L. Yuan, and Y. Yang, “Velocity vector imaging in assessing the regional systolic function of patients with post myocardial infarction,” Echocardiography, vol. 24, no. 9, pp. 940–945, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. B. H. Amundsen, T. Helle-Valle, T. Edvardsen et al., “Noninvasive myocardial strain measurement by speckle tracking echocardiography: validation against sonomicrometry and tagged magnetic resonance imaging,” Journal of the American College of Cardiology, vol. 47, no. 4, pp. 789–793, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. V. Mor-Avi, R. M. Lang, L. P. Badano et al., “Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications: endorsed by the Japanese Society of Echocardiography,” Journal of the American Society of Echocardiography, vol. 24, no. 3, pp. 277–313, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Urheim, T. Edvardsen, H. Torp, B. Angelsen, and O. A. Smiseth, “Myocardial strain by Doppler echocardiography: validation of a new method to quantify regional myocardial function,” Circulation, vol. 102, no. 10, pp. 1158–1164, 2000. View at Publisher · View at Google Scholar · View at Scopus
  41. T.-H. Park, S. F. Nagueh, D. S. Khoury et al., “Impact of myocardial structure and function postinfarction on diastolic strain measurements: implications for assessment of myocardial viability,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 290, no. 2, pp. H724–H731, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. R. Kramann, J. Erpenbeck, R. K. Schneider et al., “Speckle tracking echocardiography detects uremic cardiomyopathy early and predicts cardiovascular mortality in ESRD,” Journal of the American Society of Nephrology, vol. 25, no. 10, pp. 2351–2365, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. B. Pirat, H. Bozbas, V. Simsek et al., “Assessment of myocardial mechanics in patients with end-stage renal disease and renal transplant recipients using speckle tracking echocardiography,” Experimental and Clinical Transplantation, vol. 13, supplement 1, pp. 235–241, 2015. View at Publisher · View at Google Scholar · View at Scopus
  44. R. Chen, X. Wu, L.-J. Shen et al., “Left ventricular myocardial function in hemodialysis and nondialysis uremia patients: a three-dimensional speckle-tracking echocardiography study,” PLoS ONE, vol. 9, no. 6, Article ID e100265, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. P. Yan, H. Li, C. Hao et al., “2D-Speckle tracking echocardiography contributes to early identification of impaired left ventricular myocardial function in patients with chronic kidney disease,” Nephron—Clinical Practice, vol. 118, no. 3, pp. c232–c240, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. Y.-W. Liu, C.-T. Su, Y.-Y. Huang et al., “Left ventricular systolic strain in chronic kidney disease and hemodialysis patients,” American Journal of Nephrology, vol. 33, no. 1, pp. 84–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. J. Aoki, Y. Ikari, H. Nakajima et al., “Clinical and pathologic characteristics of dilated cardiomyopathy in hemodialysis patients,” Kidney International, vol. 67, no. 1, pp. 333–340, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. R. Leischik, B. Dworrak, and K. O. Hensel, “Intraobserver and interobserver reproducibility for radial, circumferential and longitudinal strain echocardiography,” Open Cardiovascular Medicine Journal, vol. 8, no. 1, pp. 102–109, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. E. Gayat, H. Ahmad, L. Weinert, R. M. Lang, and V. Mor-Avi, “Reproducibility and inter-vendor variability of left ventricular deformation measurements by three-dimensional speckle-tracking echocardiography,” Journal of the American Society of Echocardiography, vol. 24, no. 8, pp. 878–885, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. J. N. Khan, A. Singh, S. A. Nazir, P. Kanagala, A. H. Gershlick, and G. P. McCann, “Comparison of cardiovascular magnetic resonance feature tracking and tagging for the assessment of left ventricular systolic strain in acute myocardial infarction,” European Journal of Radiology, vol. 84, no. 5, pp. 840–848, 2015. View at Publisher · View at Google Scholar · View at Scopus
  51. N. C. Edwards, A. Noori, C. D. Chue et al., “Impaired circumferential and longitudinal myocardial deformation in early stage chronic kidney disease: the earliest features of uremic cardiomyopathy,” Journal of Cardiovascular Magnetic Resonance, vol. 15, no. S1, article P153, 2013. View at Publisher · View at Google Scholar
  52. P. B. Mark, N. Johnston, B. A. Groenning et al., “Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging,” Kidney International, vol. 69, no. 10, pp. 1839–1845, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. J. W. Mimbs, M. O'Donnell, D. Bauwens, J. W. Miller, and B. E. Sobel, “The dependence of ultrasonic attenuation and backscatter on collagen content in dog and rabbit hearts,” Circulation Research, vol. 47, no. 1, pp. 49–58, 1980. View at Publisher · View at Google Scholar · View at Scopus
  54. J. W. Mimbs, M. O'Donnell, J. G. Miller, and B. E. Sobel, “Detection of cardiomyopathic changes induced by doxorubicin based on quantitative analysis of ultrasonic backscatter,” The American Journal of Cardiology, vol. 47, no. 5, pp. 1056–1060, 1981. View at Publisher · View at Google Scholar · View at Scopus
  55. J. Naito, T. Masuyama, T. Mano et al., “Ultrasonic myocardial tissue characterization in patients with dilated cardiomyopathy: value in noninvasive assessment of myocardial fibrosis,” American Heart Journal, vol. 131, no. 1, pp. 115–121, 1996. View at Publisher · View at Google Scholar · View at Scopus
  56. E. Picano, G. Pelosi, M. Marzilli et al., “In vivo quantitative ultrasonic evaluation of myocardial fibrosis in humans,” Circulation, vol. 81, no. 1, pp. 58–64, 1990. View at Publisher · View at Google Scholar · View at Scopus
  57. R. H. Hoyt, S. M. Collins, D. J. Skorton, E. E. Ericksen, and D. Conyers, “Assessment of fibrosis in infarcted human hearts by analysis of ultrasonic backscatter,” Circulation, vol. 71, no. 4, pp. 740–744, 1985. View at Publisher · View at Google Scholar · View at Scopus
  58. D. L. Prior, J. B. Somaratne, A. J. Jenkins et al., “Calibrated integrated backscatter and myocardial fibrosis in patients undergoing cardiac surgery,” Open Heart, vol. 2, no. 1, Article ID e000278, 2015. View at Publisher · View at Google Scholar
  59. F. Lattanzi, E. Picano, A. Mazzarisi et al., “In vivo radiofrequency ultrasound analysis of normal human heart structures,” Journal of Clinical Ultrasound, vol. 15, no. 6, pp. 371–375, 1987. View at Publisher · View at Google Scholar · View at Scopus
  60. M. Salvetti, M. L. Muiesan, A. Paini et al., “Myocardial ultrasound tissue characterization in patients with chronic renal failure,” Journal of the American Society of Nephrology, vol. 18, no. 6, pp. 1953–1958, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. M. A. Losi, B. Memoli, C. Contaldi et al., “Myocardial fibrosis and diastolic dysfunction in patients on chronic haemodialysis,” Nephrology Dialysis Transplantation, vol. 25, no. 6, pp. 1950–1954, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. X. Jin, S. Rong, C. Mei, C. Ye, J. Chen, and X. Chen, “Effects of thrice-weekly in-center nocturnal vs. conventional hemodialysis on integrated backscatter of myocardial tissue,” Hemodialysis International, vol. 15, no. 2, pp. 200–210, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. S. Bull, S. K. White, S. K. Piechnik et al., “Human non-contrast T1 values and correlation with histology in diffuse fibrosis,” Heart, vol. 99, no. 13, pp. 932–937, 2013. View at Publisher · View at Google Scholar · View at Scopus
  64. T. D. Karamitsos, S. K. Piechnik, S. M. Banypersad et al., “Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis,” JACC: Cardiovascular Imaging, vol. 6, no. 4, pp. 488–497, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. S. Dass, J. J. Suttie, S. K. Piechnik et al., “Myocardial tissue characterization using magnetic resonance noncontrast T1 mapping in hypertrophic and dilated cardiomyopathy,” Circulation: Cardiovascular Imaging, vol. 5, no. 6, pp. 726–733, 2012. View at Publisher · View at Google Scholar · View at Scopus
  66. S. Pica, D. M. Sado, V. Maestrini et al., “Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance,” Journal of Cardiovascular Magnetic Resonance, vol. 16, no. 1, 2014. View at Publisher · View at Google Scholar
  67. A. Kali, I. Cokic, R. L. Q. Tang et al., “Determination of location, size, and transmurality of chronic myocardial infarction without exogenous contrast media by using cardiac magnetic resonance imaging at 3 T,” Circulation: Cardiovascular Imaging, vol. 7, no. 3, pp. 471–481, 2014. View at Publisher · View at Google Scholar · View at Scopus
  68. D. M. Sado, V. Maestrini, S. K. Piechnik et al., “Noncontrast myocardial T1 mapping using cardiovascular magnetic resonance for iron overload,” Journal of Magnetic Resonance Imaging, vol. 41, no. 6, pp. 1505–1511, 2015. View at Publisher · View at Google Scholar · View at Scopus
  69. V. M. Ferreira, S. K. Piechnik, E. Dall'Armellina et al., “T1 mapping for the diagnosis of acute myocarditis using CMR: comparison to T2-weighted and late gadolinium enhanced imaging,” JACC: Cardiovascular Imaging, vol. 6, no. 10, pp. 1048–1058, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. E. Rutherford, M. A. Talle, K. Mangion et al., “Defining myocardial tissue abnormalities in end-stage renal failure with cardiac magnetic resonance imaging using native T1 mapping,” Kidney International, vol. 90, no. 4, pp. 845–852, 2016. View at Publisher · View at Google Scholar
  71. M. P. Graham-Brown, D. S. March, D. R. Churchward et al., “Novel cardiac nuclear magnetic resonance method for noninvasive assessment of myocardial fibrosis in hemodialysis patients,” Kidney International, vol. 90, no. 4, pp. 835–844, 2016. View at Publisher · View at Google Scholar
  72. S. Dai, N. A. Ayres, R. B. Harrist, J. T. Bricker, and D. R. Labarthe, “Validity of echocardiographic measurement in an epidemiological study: project HeartBeat!,” Hypertension, vol. 34, no. 2, pp. 236–241, 1999. View at Publisher · View at Google Scholar · View at Scopus
  73. T. C. Gillebert, A. F. Leite-Moreira, and S. G. De Hert, “Relaxation-systolic pressure relation: a load-independent assessment of left ventricular contractility,” Circulation, vol. 95, no. 3, pp. 745–752, 1997. View at Publisher · View at Google Scholar · View at Scopus
  74. F. Grothues, G. C. Smith, J. C. C. Moon et al., “Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy,” American Journal of Cardiology, vol. 90, no. 1, pp. 29–34, 2002. View at Publisher · View at Google Scholar · View at Scopus
  75. P. Croisille, D. Revel, and M. Saeed, “Contrast agents and cardiac MR imaging of myocardial ischemia: from bench to bedside,” European Radiology, vol. 16, no. 9, pp. 1951–1963, 2006. View at Publisher · View at Google Scholar · View at Scopus
  76. R. M. Judd, M. K. Atalay, G. A. Rottman, and E. A. Zerhouni, “Effects of myocardial water exchange on T1 enhancement during bolus administration of MR contrast agents,” Magnetic Resonance in Medicine, vol. 33, no. 2, pp. 215–223, 1995. View at Publisher · View at Google Scholar · View at Scopus
  77. E. Kehr, M. Sono, S. S. Chugh, and M. Jerosch-Herold, “Gadolinium-enhanced magnetic resonance imaging for detection and quantification of fibrosis in human myocardium in vitro,” International Journal of Cardiovascular Imaging, vol. 24, no. 1, pp. 61–68, 2008. View at Publisher · View at Google Scholar · View at Scopus
  78. J. C. Moon, D. R. Messroghli, P. Kellman et al., “Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement,” Journal of Cardiovascular Magnetic Resonance, vol. 15, no. 1, article 92, 2013. View at Publisher · View at Google Scholar · View at Scopus
  79. P. Kellman, J. R. Wilson, H. Xue, M. Ugander, and A. E. Arai, “Extracellular volume fraction mapping in the myocardium, part 1: evaluation of an automated method,” Journal of Cardiovascular Magnetic Resonance, vol. 14, no. 1, article no. 63, 2012. View at Publisher · View at Google Scholar · View at Scopus
  80. R. Bruce, A. L. Wentland, A. K. Haemel et al., “Incidence of nephrogenic systemic fibrosis using gadobenate dimeglumine in 1423 patients with renal insufficiency compared with gadodiamide,” Investigative Radiology, vol. 51, no. 11, pp. 701–705, 2016. View at Publisher · View at Google Scholar · View at Scopus
  81. C. L. Bennett, Z. P. Qureshi, A. O. Sartor et al., “Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease,” Clinical Kidney Journal, vol. 5, no. 1, pp. 82–88, 2012. View at Publisher · View at Google Scholar · View at Scopus
  82. J. Kay, “Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction,” Annals of the Rheumatic Diseases, vol. 67, no. 3, pp. iii66–iii69, 2008. View at Publisher · View at Google Scholar · View at Scopus
  83. J. C. C. Moon and S. K. Prasad, “Cardiovascular magnetic resonance and the evaluation of heart failure,” Current Cardiology Reports, vol. 7, no. 1, pp. 39–44, 2005. View at Publisher · View at Google Scholar · View at Scopus
  84. L. Iles, H. Pfluger, A. Phrommintikul et al., “Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping,” Journal of the American College of Cardiology, vol. 52, no. 19, pp. 1574–1580, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. M. Graham-Brown, J. Burton, and G. McCann, “The use of T1 mapping to define myocardial fibrosis in haemodialysis patients,” European Heart Journal—Cardiovascular Imaging, vol. 17, no. 7, article 832, 2016. View at Publisher · View at Google Scholar
  86. N. C. Edwards, W. E. Moody, M. Yuan et al., “Diffuse interstitial fibrosis and myocardial dysfunction in early chronic kidney disease,” American Journal of Cardiology, vol. 115, no. 9, pp. 1311–1317, 2015. View at Publisher · View at Google Scholar · View at Scopus
  87. M. P. Graham-Brown, E. Rutherford, E. Levelt et al., “Native T1 mapping: inter-study, inter-observer and inter-center reproducibility in hemodialysis patients,” Journal of Cardiovascular Magnetic Resonance, vol. 19, no. 1, article 21, 2017. View at Publisher · View at Google Scholar
  88. L. Wang, J. Yuan, S.-J. Zhang et al., “Myocardial T1rho mapping of patients with end-stage renal disease and its comparison with T1 mapping and T2 mapping: a feasibility and reproducibility study,” Journal of Magnetic Resonance Imaging, vol. 44, no. 3, pp. 723–731, 2016. View at Publisher · View at Google Scholar · View at Scopus
  89. D. Dabir, N. Child, A. Kalra et al., “Reference values for healthy human myocardium using a T1 mapping methodology: results from the International T1 Multicenter cardiovascular magnetic resonance study,” Journal of Cardiovascular Magnetic Resonance, vol. 16, no. 1, article no. 69, 2014. View at Publisher · View at Google Scholar · View at Scopus
  90. D. M. Sado, A. S. Flett, and J. C. Moon, “Novel imaging techniques for diffuse myocardial fibrosis,” Future Cardiology, vol. 7, no. 5, pp. 643–650, 2011. View at Publisher · View at Google Scholar · View at Scopus
  91. G. A. Stewart, J. Foster, M. Cowan et al., “Echocardiography overestimates left ventricular mass in hemodialysis patients relative to magnetic resonance imaging,” Kidney International, vol. 56, no. 6, pp. 2248–2253, 1999. View at Publisher · View at Google Scholar · View at Scopus
  92. H. Schmitt-Willich, “Stability of linear and macrocyclic gadolinium based contrast agents,” British Journal of Radiology, vol. 80, no. 955, pp. 581–583, 2007. View at Publisher · View at Google Scholar · View at Scopus